Short-acting β₂-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.

ABSTRACT:

Background

To gain a global perspective on short-acting β₂-agonist (SABA) prescriptions and associated asthma-related clinical outcomes in patients with asthma, we assessed primary health data across 24 countries in five continents.

Methods

SABINA III was a cross-sectional study that employed electronic case report forms at a study visit (in primary or specialist care) to record prescribed medication(s), over-the-counter (OTC) SABA purchases and clinical outcomes in asthma patients (≥12 years old) during the past 12 months. In patients with ≥1 SABA prescriptions, associations of SABA with asthma symptom control and severe exacerbations were analysed using multivariable regression models.

Results

Of 8351 patients recruited (n=6872, specialists; n=1440, prima

SUBMITTER: Bateman ED 

PROVIDER: S-EPMC9068976 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature